Welcome to The Multiple Sclerosis Journey. Join us for a multimedia exploration of where MS treatment and research stands, what the future of care may hold, and the experiences of clinicians and patients as they collaborate on the frontlines of MS care.

The Multiple Sclerosis Journey will examine new insights on the importance of early diagnosis as well as accurate identification of the four MS phenotypes and how their recognition impacts treatment selection. Join us as we examine the importance of maintaining brain health in sustaining wellness and ability among patients with MS. Experience discussions of the role of patient and physician collaboration in sustaining continuity of care and in tailoring therapy to individual patient needs and preferences.

And, importantly, view the impact of MS through the eyes of individual patients who generously tell their stories of how they build their lives around their abilities, not their disabilities.

The road to a cure for MS lies ahead. Along the way, clinicians, physicians, and patients are sharing their stories of working toward that goal at The Multiple Sclerosis Journey. We invite you to join them.

Walk with us.

Featured Articles

Gadolinium warning leaves MS patients, doctors more cautious about scans

Specialists urge continued use of MRI with GBCAs to detect otherwise hidden signs of progression

When MS affects sex and intimacy

At first, Seattle-area resident Kellen Prouse blamed himself when sex became an ordeal after he was diagnosed with primary progressive multiple sclerosis. “I’m 27, and I’m saying, ‘What is wrong?’ It was hard to admit it was part of MS at first.”

Vitamin D: Will ongoing studies provide enough high-quality evidence to assess efficacy in MS?

Vitamin D supplements are safe, but there’s not enough high-quality evidence that vitamin D is effective for slowing the progression of multiple sclerosis, a Cochrane analysis recently concluded. The results from ongoing prospective studies may provide the answers that address vitamin D’s role for MS patients.

Dual studies will track long-term responses to aggressive and first-line MS treatments

A pair of studies aims to determine whether early, aggressive treatment can improve long term outcomes for patients diagnosed with relapsing-remitting multiple sclerosis.

Guiding the decision to use disease-modifying therapies

Neurologists and patients with multiple sclerosis are on the horns of a dilemma: How to best employ new disease-modifying drugs that are potent enough to induce life-changing remissions and too new to have amassed long-term safety data.